CYP2E1 and cancer: After intraperitoneal administration, DEN is metabolized by cytochrome P450 (CYP2E1) in the liver, yielding an active mutagenic metabolite that can directly bind to nucleic acids, resulting in DNA mutation and cancer formation [21].